Literature DB >> 10677393

Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats.

N D Duncan1, D A Williams, G S Lynch.   

Abstract

The beta(2)-adrenergic agonist, clenbuterol, has powerful muscle anabolic and lipolytic effects and is used by athletes to improve exercise performance; however, its use in conjunction with different forms of exercise training has received limited attention. Since previous studies have reported that chronic use of other beta(2)-adrenergic agonists has deleterious effects on cardiac muscle structure and function, the aim of the present study was to determine whether chronic clenbuterol administration would reduce the exercise capabilities of rats subjected to long-term treadmill sprint running, endurance swimming or voluntary wheel running training. The effect of clenbuterol treatment on exercise performance in rats was evaluated in three separate studies. Different groups of male rats were assigned to an endurance swimming (2 h/day, 5/7 days, 18 weeks) group, a treadmill sprint running (8x1 min bouts, 1.05 m/s, 20 weeks) group, or a voluntary wheel running (16 weeks) group. In each study, rats were allocated into either a treated group that received clenbuterol (2 mg.kg(-1).day(-1)) in their drinking water or an untreated control group. In each of the three studies, treated rats exhibited a reduction in exercise performance compared with untreated rats. Treated rats ran approximately 57% less total distance than untreated rats in the voluntary running programme and were unable to complete the swimming and sprinting protocols performed by the untreated rats. In each of the studies, the treated rats exhibited cardiac hypertrophy, with absolute heart mass increased by approximately 19% and heart mass relative to body mass increased by approximately 20%. The hearts of sedentary rats treated with clenbuterol exhibited extensive collagen infiltration surrounding blood vessels and in the wall of the left ventricle. The results indicate strongly that chronic clenbuterol administration deleteriously affects exercise performance in rats, potentially due to alterations in cardiac muscle structure and function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677393

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  13 in total

1.  Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.

Authors:  James G Ryall; Martin N Sillence; Gordon S Lynch
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 2.  The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

Authors:  E Davis; R Loiacono; R J Summers
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

3.  Grip force, EDL contractile properties, and voluntary wheel running after postdevelopmental myostatin depletion in mice.

Authors:  Kirkwood E Personius; Aditi Jayaram; David Krull; Roger Brown; Tianshun Xu; Bajin Han; Kerri Burgess; Christopher Storey; Bharati Shah; Rabi Tawil; Stephen Welle
Journal:  J Appl Physiol (1985)       Date:  2010-07-01

4.  Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses.

Authors:  David R Plant; Charles F Kearns; Kenneth H McKeever; Gordon S Lynch
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

5.  Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.

Authors:  James G Ryall; David R Plant; Paul Gregorevic; Martin N Sillence; Gordon S Lynch
Journal:  J Physiol       Date:  2003-11-14       Impact factor: 5.182

6.  Chronic β2 -adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men.

Authors:  Morten Hostrup; Johan Onslev; Glenn A Jacobson; Richard Wilson; Jens Bangsbo
Journal:  J Physiol       Date:  2017-11-12       Impact factor: 5.182

7.  Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol.

Authors:  Jatin G Burniston; Neil Chester; William A Clark; Lip-Bun Tan; David F Goldspink
Journal:  Muscle Nerve       Date:  2005-12       Impact factor: 3.217

8.  Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle.

Authors:  Jatin G Burniston; Lynn McLean; Robert J Beynon; David F Goldspink
Journal:  Muscle Nerve       Date:  2007-02       Impact factor: 3.217

9.  Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles.

Authors:  Jatin G Burniston; William A Clark; Lip-Bun Tan; David F Goldspink
Journal:  Muscle Nerve       Date:  2006-05       Impact factor: 3.217

10.  Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle.

Authors:  Pascal Sirvent; Aymerick Douillard; Olivier Galbes; Christelle Ramonatxo; Guillaume Py; Robin Candau; Alain Lacampagne
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.